EUCTR2017-000657-39-GB进行中（未招募）1 期
Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid induced constipation - NAXOS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 563
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria at Visit 1:
- •1 - Male or Female >18 years of age with OIC
- •2 - Long-term WHO step III opioid therapy for at least 3 months prior to screening for treatment of chronic non-cancer pain
- •3 - Receiving a stable maintenance regimen with one long-acting oral or transdermal WHO step III opioid (except tapentadol) consisting of a total daily dose of =40mg morphine equivalent for a minimum of 4 weeks prior with no anticipated change in opioid dose requirement over the proposed trial period
- •4 - Symptoms of constipation with onset after the start of opioid medication for at least the last 4 week prior to screening:
- •All of the following:
- •- <3 spontaneous bowel movements per week
- •- loose stools are rarely present without the use of laxatives
- •Two or more of the following:
- •- straining during at least 25% of defecations
- •- lumpy or hard stools in at least 25% of defecations
- •- sensation of incomplete evacuation in at least 25% of defecations
- •- sensation of anorectal obstruction for a least 25% of defecations
- •- manual manoeuvres for at least 25% of defecations
- •5 - Willingness to stop at V2 all laxatives, enemas, stool softeners, and any other medications used to treat constipation with the exception of laxative rescue medication (i.e., bisacodyl tablets) allowed per protocol.
- •6 - Patients willing and able (e.g. mental and physical condition) to participate in all aspects of the trial, including use of medication, correct and independent completion of subjective evaluations (e.g. electronic diary, eDiary), attending scheduled visits, completing telephone interviews, and compliant with all protocol requirements, as evidenced by providing signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1044
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 448
排除标准
- •1. History of cancer in the last 2 years except basal cell carcinoma and non-metastatic squamous cell skin cancer. Patients with any malignancy in the past are eligible in case they have been continuously disease-free for at least 2 years.
- •2. Known or suspected reason for constipation other than OIC (e.g.idiopathic, neurological, endocrine, or metabolic).
- •3. Known or suspected medical conditions that might be associated with diarrhoea, intermittent loose stools or constipation, such as faecal incontinence or irritable bowel syndrome (IBS). In case of documented suspicion of IBS or justified doubts of a long ago diagnosis, the Rome IV criteria must be applied).
- •4. Any known or suspected gastrointestinal (GI) pathology that might increase the risk of perforation, such as chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis), acute diverticulitis or history of > 1 episode of diverticulitis, intestinal obstruction or pseudoobstruction.
- •5. Any form of acute temporary or permanent GI ostomy, such as ileostomy or colostomy.
- •6. Renal impairment requiring any form of dialysis.
- •7. Known or suspected moderate-to-severe hepatic impairment (serum total bilirubin > 2 upper limit of normal (ULN) except in patients diagnosed with Gilbert's syndrome, International Normalised Ratio (INR) > 2 ULN (except in patients on therapeutic anti-coagulation), serum albumin < 2.8 g/dL)
- •8. Presence of any other significant or progressive/unstable medical condition that, in the opinion of the investigator, would compromise evaluation of the trial treatment or may jeopardise patient's safety, compliance or adherence to protocol requirements, such as significant psychiatric, cardiovascular, pulmonary, metabolic, endocrine or neurological disease.
- •9. Any GI pathology or surgery or intractable vomiting likely to significantly influence drug absorption.
- •10. Inability to swallow the trial medication whole (e.g. due to dysphagia).
- •11. Known or suspected acute or chronic alcoholism, delirium tremens,or toxic psychosis.
- •12. Signs and symptoms that may be related to opioid withdrawal.
- •13. Use of prohibited medication or treatments as defined in the list of not allowed medication or treatments.
- •14. For women: Pregnancy or breast-feeding. Women of childbearing potential unable or unwilling to undergo pregnancy tests and practice acceptable contraceptive measures. For men: Men unable or unwilling to practice acceptable contraceptive measures.
- •15. Previous enrolment in this trial or participation in any other drug investigational trial within the past 30 days
- •16. Previous treatment in a clinical trial with Naloxone HCl PR Tablets (except one re-screening in this trial).
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200